- Cardinal Health recently reported fourth-quarter and full-year 2026 results, with full-year sales of US$254.25 billion and net income of US$1.71 billion, alongside a US$0.5158 quarterly dividend declaration and a new US$4.00 billion revolving credit facility.
- The company also completed a prior US$2.08 billion buyback and launched a fresh US$5.00 billion repurchase authorization, signaling management’s focus on returning capital while maintaining expanded liquidity.
- We’ll now examine how this combination of earnings growth, a larger buyback plan, and expanded credit access may influence Cardinal Health’s investment narrative.
Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
Cardinal Health Investment Narrative Recap
To own Cardinal Health, you need to believe in its role as a large-scale pharmaceutical and medical distributor that can manage thin margins, tight regulation and customer concentration. The latest results and capital moves do not materially change the key near term catalyst around execution in its Global Medical Products and Distribution segment, while regulatory and pricing pressure remains the biggest overarching risk.
The new US$4.0 billion revolving credit facility stands out here, as it replaces several smaller lines and a receivables program with a single, longer dated source of liquidity. For investors focused on how Cardinal funds US$700 million of planned capital expenditures and at least US$1.0 billion of share repurchases, this facility helps frame the balance sheet’s capacity to support those near term plans without directly addressing longer term regulatory risks.
Yet while capital returns and liquidity look well supported, investors should be aware of the risk that pricing and reimbursement reforms could...
Read the full narrative on Cardinal Health (it's free!)
Cardinal Health's narrative projects $302.9 billion revenue and $2.4 billion earnings by 2029. This requires 6.0% yearly revenue growth and about a $0.7 billion earnings increase from $1.7 billion today.
Uncover how Cardinal Health's forecasts yield a $264.73 fair value, a 14% upside to its current price.
Exploring Other Perspectives
Three fair value estimates from the Simply Wall St Community span roughly US$265 to US$739 per share, showing how far apart views on Cardinal Health can be. Against this wide range, the ongoing risk of tighter government pricing and reimbursement rules could have important implications for how its recent earnings and capital return plans translate into future performance, so it makes sense to compare several viewpoints before forming a view of your own.
Explore 3 other fair value estimates on Cardinal Health - why the stock might be worth over 3x more than the current price!
The Verdict Is Yours
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Cardinal Health research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
- Our free Cardinal Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cardinal Health's overall financial health at a glance.
Seeking Other Investments?
Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:
- Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.
- The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
- AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com